D S-W Tan
Overview
Explore the profile of D S-W Tan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
127
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rodon Ahnert J, Tan D, Garrido-Laguna I, Harb W, Bessudo A, Beck J, et al.
ESMO Open
. 2023 Jun;
8(4):101584.
PMID: 37379764
Background: Combinations of avelumab [anti-programmed death-ligand 1 (anti-PD-L1)] or talazoparib [poly(adenosine diphosphate ribose) polymerase (PARP) inhibitor] with binimetinib (MEK inhibitor) were expected to result in additive or synergistic antitumor activity...
2.
Tan D, Thomas M, Kim D, Szpakowski S, Urban P, Mehra R, et al.
Lung Cancer
. 2021 Dec;
163:7-13.
PMID: 34890832
Objectives: To better understand genetic determinants of response to ceritinib, an exploratory analysis was conducted using tumor biopsies from anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small-cell lung cancer (NSCLC) patients treated...
3.
Lin J, Liu S, McCoach C, Zhu V, Tan A, Yoda S, et al.
Ann Oncol
. 2020 Oct;
31(12):1725-1733.
PMID: 33007380
Background: Rearranged during transfection (RET) gene fusions are a validated target in non-small-cell lung cancer (NSCLC). RET-selective inhibitors selpercatinib (LOXO-292) and pralsetinib (BLU-667) recently demonstrated favorable antitumor activity and safety...
4.
Kaye S, Aamdal S, Jones R, Freyer G, Pujade-Lauraine E, de Vries E, et al.
Br J Cancer
. 2012 Apr;
106(11):1728-34.
PMID: 22531637
Background: As a prelude to combination studies aimed at resistance reversal, this dose-escalation/dose-expansion study investigated the selective Src kinase inhibitor saracatinib (AZD0530) in combination with carboplatin and/or paclitaxel. Methods: Patients...